Abstract: This application relates to biological pharmacy and biochemical engineering, and more particularly to a method of preparing a (S)-1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline compound. This method includes: subjecting a 1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline raceme as a substrate to selective oxidation in the presence of a monoamine oxidase and the non-selective reduction to prepare the (S)-1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline compound, where the monoamine oxidase has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence having an identity of more than 80% with SEQ ID NO: 1. The kinetic resolution is carried out in the presence of the monoamine oxidase as a catalyst and a reductant, and the resulting product has a high chiral purity.

Abstract: The present application relates to a method for fermentative production of oxidized coenzyme Q10 and high-content oxidized coenzyme Q10 prepared therefrom. For the method for fermentative production of oxidized coenzyme Q10, in a fermentation process of a production strain, the oxidation-reduction potential (ORP) of a fermentation broth is controlled to be ?50 to 300 Mv, and preferably the oxidation-reduction potential (ORP) of the fermentation broth is controlled to be 50 to 200 mV. By controlling the ORP of the fermentation broth, the method for fermentative production of oxidized coenzyme Q10 enables the oxidized coenzyme Q10 content in the coenzyme Q10 produced by microorganisms to reach 96% or more, and the product is substantially composed of a single component, which makes post-treatment more convenient.

Abstract: A process for producing reduced coenzyme Q10 includes removing moisture from an aqueous suspension including a reduced coenzyme Q10-containing microbial cell or a disrupted cell thereof such that a de-moisturized substance is obtained and in contact with an oxidizing atmosphere, and that an oxidized coenzyme Q10 is produced in an amount of 50 mass % or more relative to a total amount of the oxidized and reduced coenzymes Q10, and reducing the oxidized coenzyme Q10 outside a microbial cell such that a reduced coenzyme Q10 is recovered.

Abstract: A process for producing on an industrial scale the oxidized coenzyme Q10, includes culturing a reduced coenzyme Q10-producing microorganism selected from the group consisting of the genus Rhodobacter, the genus Saitoella, the genus Schizosaccharomyces and the genus Trichosporon, to obtain microbial cells containing reduced coenzyme Q10 at a ratio of not less than 70 mole % among the entire coenzymes Q10; and one of: (a) oxidizing thus-obtained reduced coenzyme Q10 to oxidized coenzyme Q10 and then extracting the oxidized coenzyme Q10 by an organic solvent; or (b) extracting reduced coenzyme Q10 by an organic solvent and oxidizing the extracted reduced coenzyme Q10 to oxidized coenzyme Q10.

Abstract: The invention features methods for producing isoprene from cultured cells using a feedback-resistant mevalonate kinase polypeptide, such as an archaeal mevalonate kinase polypeptide. The resulting isoprene compositions may have increased yields and/or purity of isoprene.

Abstract: The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, cashew nut, and Asian lacquer.

Abstract: Disclosed is a pharmaceutical natural composition containing both statin compounds (mevinolin and mevinolinic acid) serving as cholesterol biosynthesis inhibitors and coenzyme Q (ubiquinone-10: CoQ10 and ubiquinone-9: CoQ9) compounds which are substances that inhibit factors causing complications such as myalgia involved in long-term use of the statin, prepared using Monascus sp. and natural medicinal substances such as ginseng, mushrooms and cereals.

Abstract: A method for producing coenzyme Q10 by using stock culture from solid phase fermentation. The strain used in this method is Rhodobacter sphaeroides. Strain passaging is carried out by culturing in a slant medium. After steam cooking and air drying, solid medium is subpackaged and sterilized, wherein said solid medium includes solid components and liquid components. The fresh culture of Rhodobacter sphaeroides on the slant medium is added with sterile water, and the resultant bacterial suspension is added into the solid medium, cultured and used as stock culture for primary fermentation. The method of the present invention can enhance the fermentation level of coenzyme Q10, reduce the cascades of fermentation, shorten production cycle, simplify production processes, and lower production cost.

Abstract: Disclosed herein are transformed Yarrowia lipolytica comprising an exogenous polynucleotide encoding a polypeptide having sucrose invertase activity. Also disclosed are methods of using the transformed Y. lipolytica.

Abstract: A method for producing coenzyme Q10 by using stock culture from solid phase fermentation. The strain used in this method is Rhodobacter sphaeroides. Strain passaging is carried out by culturing in a slant medium. After steam cooking and air drying, solid medium is subpackaged and sterilized, wherein said solid medium includes solid components and liquid components. The fresh culture of Rhodobacter sphaeroides on the slant medium is added with sterile water, and the resultant bacterial suspension is added into the solid medium, cultured and used as stock culture for primary fermentation. The method of the present invention can enhance the fermentation level of coenzyme Q10, reduce the cascades of fermentation, shorten production cycle, simplify production processes, and lower production cost.

Abstract: A method for producing a food product containing nattokinase but containing little or none vitamin K2, comprising treating a Bacillus natto culture or culture supernatant with at least one coagulant selected from the group consisting of an inorganic coagulant and a cationic polymer coagulant (excluding chitosan). As the inorganic coagulant, calcium chloride or poly aluminum chloride is preferable, and their mixtures with a phosphorus coagulant are also preferably used. As the cationic polymer coagulant, cationic polysaccharides, hexamethylenediamine/ephichlorohydrin polycondensates or dimethylamine/epichlorohydrin polycondensates are preferably used, and their mixtures with a polyacrylate are also preferably used.

Abstract: A fermentation method for producing coenzyme Q10 is provided, including stepwisly culturing of microbial strains capable of producing coenzyme Q10, wherein key promoting factors are added in each stage of culture, and in the stage of culture in a fermentor, dissolved oxygen feedback-fed batch culture technique is adopted to realize the feedback regulation of the production of coenzyme Q10, so as to improve the yield of coenzyme Q10.

Abstract: The present invention relates to a method of producing high-quality reduced coenzyme Q10 converted from oxidized coenzyme Q10 by natural reductase. It is stable, completely natural and can be used on injection. This method is suitable for large-scale industrial production without special protective environment/atmosphere. The method of producing reduced coenzyme Q10 includes three stages: {circle around (1)} phosphorylation of oxidized coenzyme Q10 {circle around (2)} reduction of phosphorylated oxidized coenzyme Q Q10 by biological reductase {circle around (3)} extracting reduced coenzyme Q10 from reductases.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: The present invention relates to a method for increasing the amount of K2 vitamin obtained by culturing at least one stem of a lactic bacteria that produces K2 vitamin, wherein the culture of said stem is realized in resting-cells conditions so that the amount of K2 vitamin produced by the resting-cells culture is higher by a ratio of at least 1.2 to that obtained by the culture of said stem under standard fermentation conditions. The present invention also relates to the biomass obtained from the culture of a lactic bacteria producing K2 vitamin according to the above method. The invention further relates to a method for producing K2 vitamin, to a method for preparing food products, including fermented products and/or fresh diary products, enriched with K2 vitamin, and to the food products thus obtained.

Abstract: The present disclosure describes a method of producing a long-chain prenyl diphosphate synthase (in particular decaprenyl diphosphate synthase and solanesyl diphosphate synthase) using a gene and a protein which are required for enabling or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase as well as a method of efficiently producing a coenzyme Q having a long-chain isoprenoid in its side chain (in particular coenzyme Q9 or coenzyme Q10) using a microorganism. The present disclosure also describes a DNA having a base sequence shown under SEQ ID NO:1, 3 or 5 and a DNA sequence derived from the above base sequence by deletion, addition, insertion and/or substitution of one to several bases thereof, and coding for a protein enabling (functioning) or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase in a cell of a host organism.

Abstract: A method for producing vitamin K2 comprising: culturing Bacillus natto in a liquid medium to obtain a Bacillus natto culture or culture supernatant thereof, wherein the culture or culture supernatant contains vitamin K2; treating the culture or culture supernatant with at least one coagulant selected from the group consisting of an inorganic coagulant and a cationic polymer coagulant, with the proviso that the coagulant excludes chitosan, so as to obtain a treated coagulant to which vitamin K2 is absorbed or aggregated; separating the treated coagulant from the treated culture or culture supernatant, and obtaining an oily product that contains vitamin K2 from the separated coagulant.

Abstract: The invention relates to bacterial strains having an outstanding ability to produce menaquinone and to applications thereof.

Abstract: A bioengineered synthesis scheme for the production of quinic acid from a carbon source is provided. Methods of producing quinic acid from a carbon source based on the synthesis scheme as well as conversion of quinic acid to hydroquinone are also provided.

Abstract: A new isolate of Sporidiobolus johnsonii that is capable of producing over a significant percentage of CoQ10 upon the addition of para-hydroxy benzoic acid in stationary phase, and a method of obtaining CoQ10 from the S. johnsonii isolate which can be scaled up to industrial levels.

Abstract: The present invention provides materials and methods for the growth of microorganisms for the production of organic chemicals, for example, coenzyme Q10.

Abstract: The invention relates to a method of producing menaquinone-7, characterized in that cells of an E. coli strain comprising the B. subtilis DSM 1088 hepS gene, the B. subtilis DSM 1088 hepT gene and the putative B. subtilis DSM 1088 heptaprenyl transferase gene are fermented in a fermentation medium, with menaquinone-7 being accumulated in the cells of the fermented E. coli strain.

Abstract: The present invention relates to a method of producing high-quality reduced coenzyme Q10 converted from oxidized coenzyme Q10 by natural reductase. It is stable, completely natural and can be used on injection. This method is suitable for large-scale industrial production without special protective environment/atmosphere. The method of producing reduced coenzyme Q10 includes three stages: {circumflex over (1)} phosphorylation of oxidized coenzyme Q10 {circumflex over (2)} reduction of phosphorylated oxidized coenzyme Q Q10 by biological reductase {circumflex over (3)} extracting reduced coenzyme Q10 from reductases.

Abstract: The present invention relates to a process for producing reduced coenzyme Q10 which comprises obtaining microbial cells containing reduced coenzyme Q10 at a ratio of not less than 70 mole % among the entire coenzymes Q10, optionally disrupting the cells and recovering thus-produced reduced coenzyme Q10. The present invention also relates to a process for producing oxidized coenzyme Q10 which comprises either recovering oxidized coenzyme Q10 after oxidizing the above-mentioned microbial cells or disrupted product thereof, or recovering reduced coenzyme Q10 from the above-mentioned microbial cells or disrupted product thereof to oxidize thus-obtained reduced coenzyme Q10 thereafter. According to the processes of the present invention, reduced coenzyme Q10 and oxidized coenzyme Q10 can be produced simply on the industrial scale.

Abstract: The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.

Abstract: A process for the preparation of vitamin K2 (MK-7) comprising the culture of Bacillus subtilis mutant strain GN13/72-DSM 17766 deposited on Dec. 5, 2005 at the DSMZ.

Abstract: The present invention relates to a method for increasing the amount of K2 vitamin obtained by culturing at least one stem of a lactic bacteria that produces K2 vitamin, wherein the culture of said stem is realized in resting-cells conditions so that the amount of K2 vitamin produced by the resting-cells culture is higher by a ratio of at least 1.2 to that obtained by the culture of said stem under standard fermentation conditions. The present invention also relates to the biomass obtained from the culture of a lactic bacteria producing K2 vitamin according to the above method. The invention further relates to a method for producing K2 vitamin, to a method for preparing food products, including fermented products and/or fresh diary products, enriched with K2 vitamin, and to the food products thus obtained.

Abstract: A bioengineered synthesis scheme for the production of quinic acid from a carbon source is provided. Methods of producing quinic acid from a carbon source based on the synthesis scheme as well as conversion of quinic acid to hydroquinone are also provided.

Abstract: According to the invention, Applicants have demonstrated methods for improving industrial biosynthesis of lipid soluble vitamins and nutrients. Applicants have also provided methods for cost-efficient and commercially-viable chemotherapeutic biosynthesis and purification. This invention provides novel methods for both solid mutagenesis and semi-solid fluid mutagenesis fermentation and the purification of lipid soluble vitamins and nutrients and increasing fermentation solid yields.

Abstract: The present invention provides improved processes for the preparation of Coenzyme Q-10 (CoQ10) by fermentation of microorganisms of the genus Rhodobacter transformed with the mevalonate operon of Paracoccus zeaxanthinifaciens.

Abstract: The present invention relates to a process for the production of isoprenoids Coenzyme Q-10 by microorganisms. More particularly, the present invention relates to a process for increased production of Coenzyme Q-10 by microorganisms of the genus Rhodobacter, preferably of the species R. sphaeroides which have been transformed with one or more gene(s) of the mevalonate (mev) operon from a different microorganism, preferably of the genus Paracoccus, more preferably of the species P. zeaxanthinifaciens, whereby the mev operon is mutated leading to an increased coenzyme Q-10 production. Sequences carrying such a mutation as well as a microorganism carrying such a mutated mev operon are also included.

Abstract: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of co-producing coenzyme Q10 and at least one ?-3/?-6 polyunsaturated fatty acid are provided. The strains may also be engineered to co-produce at least one C40 carotenoid. Methods of using the antioxidant products obtained (e.g., biomass and/or pigmented oils) in food and feed applications are also provided.

Abstract: The present invention provides a method of producing a long-chain prenyl diphosphate synthase (in particular decaprenyl diphosphate synthase and solanesyl diphosphate synthase) using a gene and a protein which are required for enabling or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase as well as a method of efficiently producing a coenzyme Q having a long-chain isoprenoid in its side chain (in particular coenzyme Q9 or coenzyme Q10) using a microorganism. The present invention also relates to a DNA having a base sequence shown under SEQ ID NO:1, 3 or 5 and a DNA sequence derived from the above base sequence by deletion, addition, insertion and/or substitution of one to several bases thereof, and coding for a protein enabling (functioning) or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase in a host microorganism.

Abstract: The present invention relates to a transformed Agrobacterium tumefaciens BNQ-pGPRX11 (Accession No. KCCM-10554) harboring a recombinant expression vector (pGPRX11). Further, the present invention also provides a fermentation method for maximum production of coenzyme Q10 using a transformed Agrobacterium tumefaciens deposited to Korean Culture Center of Microorganism with accession number KCCM-10554 comprising the steps of: i) constructing the recombinant expression vector pGPRX11 containing decaprenyl diphosphate synthase gene and 1-deoxy-D-xylulose 5-phosphate synthase gene (SEQ ID NO: 1); ii) preparing a transformed Agrobacterium tumefaciens (KCCM-10554) by harboring said recombinant expression vector pGPRX11 to the host of Agrobacterium tumefaciens BNQ 0605 (KCCM-10413); iii) growing the transformed cells on growth medium comprising 50 g/L of sucrose, 15 g/L of yeast extract, 15 g/L of peptone and 7.

Abstract: A Bacillus natto culture is treated with chitosan, and then filtered, concentrated, and dried. According to this method, a Bacillus natto culture extract containing nattokinase and 1 ?/g or less of vitamin K2/g dry weight is obtained.

Abstract: The present invention provides a process for producing ubiquinone-10 using a microorganism having the ability to form ubiquinone-10 and having one or more properties selected from the group consisting of the property wherein geranylgeranyltransferase activity is reduced or defective, the property wherein decaprenyldiphosphate synthetase activity is strengthened, and the property wherein p-hydroxybenzoic acid-decaprenyltransferase activity is strengthened, DNA and a polypeptide useful for the production process, microorganisms useful for the production, a method for expressing a gene in the microorganisms, and a method for breeding the microorganisms.

Abstract: The present invention provides a method of producing a long-chain prenyl diphosphate synthase (in particular decaprenyl diphosphate synthase and solanesyl diphosphate synthase) using a gene and a protein which are required for enabling or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase as well as a method of efficiently producing a coenzyme Q having a long-chain isoprenoid in its side chain (in particular coenzyme Q9 or coenzyme Q10) using a microorganism. The present invention relates to a DNA having a base sequence shown under SEQ ID NO:1, 3 or 5 and a DNA sequence derived from the above base sequence by deletion, addition, insertion and/or substitution of one to several bases thereof, and coding for a protein enabling (functioning) or enhancing the activity expression of a eukaryote-derived long-chain prenyl diphosphate synthase in a host microorganism.

Abstract: The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles; the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway.

Abstract: The present invention relates to an analysis method and analysis system that can accurately analyze the contents of coenzyme Q-10 and a 2-electron reduced form thereof in a specimen, in which human blood plasma as the specimen is mixed with isopropyl alcohol as a pretreatment and the coenzyme Q-10 and the 2-electron reduced form thereof are extracted to the isopropyl alcohol. Extracted liquid is stored at a temperature of 4° C. until the analysis is performed. The extracted liquid as an analytical sample is analyzed by an analysis system provided with a liquid-sending mechanism, a switching mechanism, a concentration column, a separation column, a reduction column, an ultraviolet absorption detector, and an electrochemical detector.

Abstract: An anti-tumor substance may be produced from a tumor cell-derived material by Staphylococcus. The anti-tumor substance may include a chemical compound having the formula: Staphylococcus may preferably be Staphylococcus lentus. Further, the tumor cell-derived material may preferably be an Ehrlich tumor cell-derived material.

Abstract: The invention aims at providing a process for producing coenzyme Q10 efficiently in microorganisms by utilizing a coenzyme Q10 side chain synthesis gene derived from a fungal species belonging to the genus Aspergillus and genus Leucosporidium. The present invention relates to a DNA having a DNA sequence described under SEQ ID NO:1 and 2 or derived from the above sequence by deletion, addition, insertion and/or substitution of one or several bases and encoding a protein having decaprenyl diphosphate synthase activity.

Abstract: A bioengineered synthesis scheme for the production of quinic acid from a carbon source is provided. Methods of producing quinic acid from a carbon source based on the synthesis scheme as well as conversion of quinic acid to hydroquinone are also provided.

Abstract: A Bacillus natto culture is treated with chitosan, and then filtered, concentrated, and dried. According to this method, a Bacillus natto culture extract containing nattokinase and 1 &mgr;g or less of vitamin K2/g dry weight is obtained.

Abstract: A method for culturing Bacillus subtilis in such a manner that a vitamin K derivative is accumulated in the largest amount in the cells of the microorganism. A method for the culture of Bacillus subtilis, which comprises culturing Bacillus subtilis and recovering the cells of the microorganism before the vitamin K produced within the cells of the microorganism is released from the cells is disclosed, as well as the cultured product of Bacillus subtilis cultured by this method, a water-soluble vitamin K derivative originating in the cultured product, a food product, beverage, or feed containing the cultured product and/or the water-soluble vitamin K derivative, and a method for extracting vitamin K.

Abstract: A method for culturing Bacillus subtilis in such a manner that a vitamin K derivative is accumulated in the largest amount in the cells of the microorganism. A method for the culture of Bacillus subtilis, which comprises culturing Bacillus subtilis and recovering the cells of the microorganism before the vitamin K produced within the cells of the microorganism is released from the cells is disclosed, as well as the cultured product of Bacillus subtilis cultured by this method, a water-soluble vitamin K derivative originating in the cultured product, a food product, beverage, or feed containing the cultured product and/or the water-soluble vitamin K derivative, and a method for extracting vitamin K.

Abstract: A bioengineered synthesis scheme for the production of quinic acid from a carbon source is provided. Methods of producing quinic acid from a carbon source based on the synthesis scheme as well as conversion of quinic acid to hydroquinone are also provided.

Abstract: A bioengineered synthesis scheme for the production of quinic acid from a carbon source is provided. Methods of producing quinic acid from a carbon source based on the synthesis scheme as well as conversion of quinic acid to hydroquinone are also provided.

Abstract: Aldose redcutase inhibitor and pharmaceutically acceptable derivatives thereof of the formula I below derived from cultures of Aspergillus niger CFR 1046 and useful as a rat lens aldose reductase inhibitor 1

Abstract: Quinone phosphoramidite reagents as well as photoreactive ketone phosphoramidite reagents, such as anthraquinone phosphoramidite reagents and benzophenone phosphoramidite reagents were synthesized and used for the solid phase synthesis of photoreactive-oligonucleotide conjugates. These phosphoramidite reagents are stable, suitable for large-scale synthesis and designed for automated solid phase synthesis of oligomers terminating in a photoreactive moiety.

Abstract: The present invention relates to novel bacterial strains useful for the production of 2-keto-L-gulonic acid. The present invention further relates to the use of these strains for the production of 2-keto-L-gulonic acid by fermentative conversion of L-sorbose. The present invention further relates to the use of these novel bacterial strains for the production of pyrroloquinoline quinone and a nontoxic lipopolysaccharide. Also described is the strains of the present invention transformed by a vector.